DUSA Pharmaceuticals to unveil BLU-U Blue Light Photodynamic Therapy Illuminator at AAD meeting

DUSA Pharmaceuticals, Inc.^® (NASDAQ GM: DUSA), a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U^® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology (AAD) meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan^® Kerastick^® topical treatment, is an integral part of the Levulan^® Photodynamic Therapy (PDT) technology platform.

Maintaining efficacy and improving ease of use among providers were paramount to the inception of the enhancements to the BLU-U, which include:

• Height adjustment using a new rotary design that allows for easier operation  
• Larger casters and a post handle for easier mobility
• A pivoting post for compact, small footprint storage and easy movement within the treatment facility

"The mechanical improvements to the BLU-U were specifically designed with practitioners in mind, while still providing them with a highly uniform, efficient, and economic blue light source to treat patients," stated BLU-U co-inventor, Scott Lundahl, DUSA's Vice-President, Regulatory Affairs and Intellectual Property.

The patented BLU-U design utilizes microprocessor feedback control to automatically deliver a consistent, uniform blue light dose to a large treatment area such as the entire face or scalp. In combination with Levulan Kerastick, it is indicated for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face or scalp.  Alone, the BLU-U is specifically cleared for the treatment of moderate inflammatory acne.